PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
Recently, immunotherapy has become the fourth pillar of cancer treatment in addition to surgery therapy, chemotherapy, and radiation therapy. The inhibitors of programed cell death protein 1 (PD-1) and its ligand PD-L1 are the new stars in immunotherapy, as they can overcome tumor immunosuppression....
Main Authors: | Yu Zhang, Guang-Ze Mou, Tian-Zhu Li, Wan-Ting Xu, Tong Zhang, Hui Xue, Wen-Bo Zuo, Yan-Nan Li, Ying-Hua Luo, Cheng-Hao Jin |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-03-01
|
Series: | Technology in Cancer Research & Treatment |
Online Access: | https://doi.org/10.1177/15330338211004942 |
Similar Items
-
Immunotoxin Monotherapy and Combinatorial Therapy With Immune Checkpoint Inhibitors for Malignant Brain Tumors
by: Bao, Xuhui
Published: (2016) -
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
by: Dongxu Wang, et al.
Published: (2019-04-01) -
Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
by: Matthias Preusser, et al.
Published: (2021-03-01) -
Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
by: Haoyang LI, et al.
Published: (2021-03-01) -
Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
by: Katarina Hradska, et al.
Published: (2021-08-01)